Edition:
India

Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

580.05INR
3:58pm IST
Change (% chg)

Rs-22.80 (-3.78%)
Prev Close
Rs602.85
Open
Rs601.85
Day's High
Rs603.90
Day's Low
Rs562.25
Volume
6,967,821
Avg. Vol
1,829,055
52-wk High
Rs704.90
52-wk Low
Rs457.45

CIPL.NS

Chart for CIPL.NS

About

Cipla Limited is a holding company. The Company is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered... (more)

Overall

Beta: 0.39
Market Cap(Mil.): Rs484,818.31
Shares Outstanding(Mil.): 804.21
Dividend: 2.00
Yield (%): 0.33

Financials

  CIPL.NS Industry Sector
P/E (TTM): 45.43 37.70 37.57
EPS (TTM): 13.27 -- --
ROI: -- 14.41 13.91
ROE: -- 15.24 14.85

MEDIA-India's Cipla to freeze increments of about 400 top managers - Economic Times

- Note: Reuters has not verified this story and does not vouch for its accuracy

29 Sep 2016

Morning News Call - India, August 16

To access the newsletter, click on the link: http://share.thomsonreuters.com/assets/newsletters/Indiamorning/MNC_IN_08162016.pdf FACTORS TO WATCH 9:30 am: RBI Governor Raghuram Rajan and Deputy Governor S.S. Mundra at FICCI-IBA annual banking conference in Mumbai. 12:00 pm: Government to release July wholesale price inflation data in New Delhi. 4:30 pm: Banks Board Bureau Chairman Vinod Rai delivers a lecture at central vigilance commission event in New Delhi.

16 Aug 2016

Cipla first quarter profit lags estimates; names new CEO

MUMBAI Cipla Ltd , India's fifth-largest drugmaker by sales, reported a lower-than-expected quarterly profit as revenues in its home market were hit by government measures to cut drug prices.

12 Aug 2016

India's Cipla Q1 profit lags estimates; names new CEO

MUMBAI, Aug 12 Cipla Ltd, India's fifth-largest drugmaker by sales, reported a lower-than-expected quarterly profit as revenues in its home market were hit by government measures to cut drug prices.

12 Aug 2016

Cipla Q4 profit lags due to one-off charges in Europe, emerging markets

MUMBAI Cipla Ltd, India's fifth-largest drugmaker by sales, reported a 69 percent fall in its quarterly profit, well below analysts' forecasts, due to one-off costs related to its business in Europe and some emerging markets.

24 May 2016

UPDATE 1-India's Cipla Q4 profit lags due to one-off charges in Europe, emerging markets

* Says exiting some emerging markets, modifying Europe business

24 May 2016

India drugmaker Cipla profit falls short of forecast, down 69 pct

MUMBAI, May 24 Cipla Ltd, India's fifth-largest drugmaker by sales, reported a fall of 69 percent in its quarterly earnings on Tuesday, far short of analysts' forecasts.

24 May 2016

Earnings vs. Estimates